The partnership hopes to speed up the scalable development of SC451 for type 1 diabetes by standardizing treatment protocols, improving clinical delivery and post-care, and preparing the therapy for broader use across...
Following their successful Phase 1, they've received clearance to begin Phase 2, where they'll assess whether it can reduce transfusion needs by calming the immune attack on bone marrow.
The Phase 1 cord blood-derived stem cell therapy for sacroiliac joint-related lower back pain showed an encouraging early safety profile and symptom improvement, supporting plans to begin Phase 2 later this year.
The trial demonstrated that Cartistem can both relieve symptoms and regenerate cartilage, and the company is advancing manufacturing readiness for its first overseas commercialization move.
Gallant said its pilot study found that intravenous stem cell therapy significantly improved pain and quality of life in cats with osteoarthritis versus placebo, supporting a faster regulatory route as the company...
The Phase II study will test XellSmart’s iPSC-derived off-the-shelf cell therapy in 30 Parkinson’s patients after Phase I showed meaningful motor and quality-of-life gains with no transplant-related adverse events.
Keck Medicine of USC is participating in a small Phase 1 clinical trial evaluating the safety and early effectiveness of implanting induced pluripotent stem cell-derived dopamine-producing cells into the brain for Parkinson’s...
Aspen’s trial advances with a commercial-ready, patient-derived cell therapy aiming to improve Parkinson’s outcomes and streamline clinical delivery.
The exPDite-2 trial will evaluate the safety and effectiveness of donor-derived stem cell therapy in Parkinson’s disease patients.
The trial will inject autologous stem cells directly into the brain to bypass the blood-brain-barrier.
